VP267

Derived from a breast cancer biopsy removed from a 48 year-old female. The histology of the breast cancer biopsy was defined as Ductal Grade III, tumour cells did not stain positive for oestrogen receptors. The VP267 cell line was derived from the same individual as the cell line VP229. VP229 was derived from the primary tumour and VP267 was derived 14 months later from a local recurrence of the tumour. The individual was recorded to live for 1year after surgery performed to remove the tumour. The patient had received tamoxifen treatment. This cell line grows slowly and is relatively difficult to culture; please read the sub-culture routine information closely.

Human Breast Cancer

STR-PCR Data: Amelogenin: X
CSF1PO: 10
D13S317: 11,13
D16S539: 11,12
D5S818: 11
D7S820: 10,12
THO1: 7
TPOX: 8
vWA: 17

MEBM (Clonetics, CC-3151) + MEGM SingleQuots (Clonetics, CC-4136) + 2mM Glutamine + 2% Foetal Bovine Serum (FBS). Fresh EGF (final concentration of 10ng/ml) should be added to the medium at each subculture.

Split sub-confluent cultures (70-80%) 1:2 i.e. seeding at 2-5x10,000 cells/cm² using 0.25% trypsin; 5% CO₂; 37°C. The VP series of breast cancer cell lines are very slow growing and relatively difficult to grow. Fresh EGF (final concentration 10ng/ml) s

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.